EirGenix Showcases Its Dual-Engine CDMO and Biosimilars Strategy at BIO International 2026
EirGenix Showcases Its Dual-Engine CDMO and Biosimilars Strategy at BIO International 2026
Highlights
- Showcased EirGenix’s dual-track strategy integrating biosimilars and commercial-scale CDMO services at BIO 2026.
- Highlighted a comprehensive HER2-positive breast cancer portfolio spanning trastuzumab, pertuzumab, subcutaneous formulations, and next-generation ADC biosimilars.
- Demonstrated an integrated biologics CDMO platform supporting clients from cell line development through commercial GMP manufacturing.
- Expanded global partnership opportunities amid biologics patent expirations and ongoing biopharma supply chain restructuring.
- Positioned EirGenix as a trusted partner accelerating global biologics development and commercialization
Read the full interview on GeneOnline | CDMO & CRO Activity US BIO 2026, 2026/06/29
2026-06-29
Associated News
DCAT Week 2026, TCA road show
EirGenix Strengthens U.S. East Coast Presence, Leveraging DCAT Week and TCA Multi-City Events to Expand Global CDMO Opportunities
2026/03/23
American Biomanufacturing Summit 2026
Top biopharma executives and solution providers come together to discuss emerging key trends, challenges, opportunities, and innovations in the biotechnology industry
2026/04/15
PEGS Boston Summit 2026, w/ TCA
EirGenix to Participate in PEGS Boston Summit 2026 and TCA Networking Events, Expanding Global Biologics CDMO Partnerships
2026/05/11
2026 Antibody Therapeutic Conference & 21st Frontiers in Biomedical Science Conference
Exploring Emerging Trends in Antibody Engineering, ADCs, Bispecific Antibodies, and Advanced Biologics Manufacturing at ATC 2026
2026/05/26
Pharma Boardroom Interview | Dr. Lee-Cheng Liu
Building Taiwan’s Next Global Biologics Champion Originally Published by Pharma Boardroom April 2026
2026/04/13
GeneOnline Interview | Dr. Potria Lin
Dr. Potria Lin discusses how EirGenix leverages its dual-engine strategy—combining CDMO services and biosimilar development—to seize opportunities arising from the global biopharma supply chain realignment.SpeakerDr. Potria LinSenior Vice President & Chief Business Officer (CBO), EirGenix
2026/06/11
BIO Asia–Taiwan 2026
EirGenix to Participate in BIO Asia–Taiwan 2026, Expanding Global Biologics CDMO Collaboration Opportunities
2026/07/16
Chinese American Biopharmaceutical Society (CABS)
Connecting with California’s Biopharma Community to Foster Strategic CDMO Partnerships and Innovation.
2026/09/19
BioProcess International Conference & Exhibition (BPI 2026)
Connecting with Global Bioprocessing Leaders at BioProcess International 2026
2026/09/22
Chinese Bioscience Association (CBA)
Engaging with Biopharma Leaders to Explore Breakthrough Technologies Advancing Human Health and Biologics Innovation.
2026/10/03
CPHI Worldwide 2026
Strengthening Strategic Global Partnerships Through CPHI Worldwide 2026
2026/10/06
BioJapan 2026
Connecting Global Innovation with Taiwan’s Advanced Biopharmaceutical Manufacturing Ecosystem at BioJapan 2026
2026/10/07
BIO-Europe (Fall) 2026
Advancing Global Biopharma Innovation and Partnership Opportunities at BIO-Europe (Fall) 2026
2026/11/09